• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尽管进行了短期肾脏替代治疗,仍发生了严重甲状旁腺功能亢进。

Development of Severe Hyperparathyroidism Despite Short-Term Renal Replacement Therapy.

作者信息

Okada Manabu, Tominaga Yoshihiro, Hiramitsu Takahisa, Ichimori Toshihiro

机构信息

Department of Transplantation and Endocrine Surgery, Nagoya Daini Red Cross Hospital, 2-9 Myoken-cho, Showa-ku, Nagoya, 4668650, Japan.

Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Japan.

出版信息

World J Surg. 2018 Feb;42(2):425-430. doi: 10.1007/s00268-017-4164-7.

DOI:10.1007/s00268-017-4164-7
PMID:28779382
Abstract

BACKGROUND

We occasionally experience cases of severe secondary hyperparathyroidism (SHPT) that require parathyroidectomy (PTX) despite undergoing short-term renal replacement therapy (RRT). Because the characteristics of such cases have never been discussed, we aimed to elucidate the pathophysiology of severe SHPT after short-term RRT by retrospectively analyzing clinical data.

METHODS

A total of 1013 patients with severe SHPT underwent PTX between January 2007 and April 2016 at Nagoya Daini Red Cross Hospital. Of these patients, 570 underwent RRT for ≥10 years (long RRT group) and 23 for ≤1 year (short RRT group). We retrospectively investigated and compared patient characteristics, preoperative data, subjective symptoms, and bone lesion incidence between the two groups.

RESULTS

A higher proportion of subjects with congenital or hereditary diseases as primary disease for chronic kidney disease (CKD) (21.7% (5/23) vs. 6.3% (36/570); P = 0.016) and longer predialysis period (21.2 ± 14.0 vs. 10.1 ± 9.2 years; P < 0.001) were observed in the short RRT group than in the long RRT group. Furthermore, lower serum calcium and phosphate levels, heavier parathyroid glands, and severe bone lesions were observed in the short RRT group than in the long RRT group.

CONCLUSION

Severe SHPT after short-term RRT appeared to occur because of long-term CKD before initiating RRT. Therefore, treating mineral and bone disorders during the early CKD stage might prevent severe SHPT development before initiating RRT.

摘要

背景

我们偶尔会遇到一些严重继发性甲状旁腺功能亢进症(SHPT)的病例,尽管这些患者接受了短期肾脏替代治疗(RRT),但仍需要进行甲状旁腺切除术(PTX)。由于此类病例的特征从未被讨论过,我们旨在通过回顾性分析临床数据来阐明短期RRT后严重SHPT的病理生理学。

方法

2007年1月至2016年4月期间,共有1013例严重SHPT患者在名古屋第二红十字医院接受了PTX。其中,570例接受RRT≥10年(长期RRT组),23例接受RRT≤1年(短期RRT组)。我们回顾性调查并比较了两组患者的特征、术前数据、主观症状和骨病变发生率。

结果

与长期RRT组相比,短期RRT组中患有先天性或遗传性疾病作为慢性肾脏病(CKD)原发性疾病的患者比例更高(21.7%(5/23)对6.3%(36/570);P = 0.016),且透析前病程更长(21.2±14.0对10.1±9.2年;P < 0.001)。此外,与长期RRT组相比,短期RRT组的血清钙和磷水平更低,甲状旁腺更重,骨病变更严重。

结论

短期RRT后的严重SHPT似乎是由于开始RRT前长期存在CKD所致。因此,在CKD早期阶段治疗矿物质和骨代谢紊乱可能会在开始RRT前预防严重SHPT的发生。

相似文献

1
Development of Severe Hyperparathyroidism Despite Short-Term Renal Replacement Therapy.尽管进行了短期肾脏替代治疗,仍发生了严重甲状旁腺功能亢进。
World J Surg. 2018 Feb;42(2):425-430. doi: 10.1007/s00268-017-4164-7.
2
Kidney Disease Improving Global Outcomes guidelines and parathyroidectomy for renal hyperparathyroidism.改善全球肾脏病预后组织(KDIGO)指南与肾性甲状旁腺功能亢进的甲状旁腺切除术
J Surg Res. 2015 Nov;199(1):115-20. doi: 10.1016/j.jss.2015.04.046. Epub 2015 Apr 18.
3
Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study.接受肾脏替代治疗患者的甲状旁腺切除术:一项流行病学研究。
J Am Soc Nephrol. 2001 Jun;12(6):1242-1248. doi: 10.1681/ASN.V1261242.
4
Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism.甲状旁腺切除术后透析患者继发性甲状旁腺功能亢进症的骨代谢标志物和饥饿骨综合征。
Int Urol Nephrol. 2019 Aug;51(8):1443-1449. doi: 10.1007/s11255-019-02217-y. Epub 2019 Jul 1.
5
[Total parathyroidectomy in treatment of Sagliker syndrome in 10 cases of hemodialysing patients with secondary hyperparathyroidism].[10例血液透析继发性甲状旁腺功能亢进患者行甲状旁腺全切除术治疗Sagliker综合征]
Zhonghua Nei Ke Za Zhi. 2011 Jul;50(7):562-7.
6
Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy.长期肾脏替代治疗患者难治性继发性甲状旁腺功能亢进危险因素的早期识别。
Nephrol Dial Transplant. 2004 May;19(5):1168-73. doi: 10.1093/ndt/gfh018. Epub 2004 Feb 19.
7
Predictive value of characteristics of resected parathyroid glands for persistent secondary hyperparathyroidism during parathyroidectomy.甲状旁腺切除术后甲状旁腺特征对持续性继发性甲状旁腺功能亢进的预测价值。
BMC Surg. 2023 Feb 14;23(1):36. doi: 10.1186/s12893-023-01936-5.
8
Survival after parathyroidectomy in chronic hemodialysis patients with severe secondary hyperparathyroidism.重度继发性甲状旁腺功能亢进的慢性血液透析患者甲状旁腺切除术后的生存情况。
Int Urol Nephrol. 2015 Nov;47(11):1871-7. doi: 10.1007/s11255-015-1106-x. Epub 2015 Sep 16.
9
Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure.有和没有肾衰竭的患者行甲状旁腺全切除术且未进行自体移植的长期结果。
Miner Electrolyte Metab. 1999 May-Jun;25(3):161-70. doi: 10.1159/000057440.
10
Relationship between parathyroid oxyphil cell proportion and clinical characteristics of patients with chronic kidney disease.甲状旁腺嗜酸细胞比例与慢性肾脏病患者临床特征的关系。
Int Urol Nephrol. 2020 Jan;52(1):155-159. doi: 10.1007/s11255-019-02330-y. Epub 2019 Nov 4.

本文引用的文献

1
Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.慢性肾脏病-矿物质和骨异常管理的临床实践指南
Ther Apher Dial. 2013 Jun;17(3):247-88. doi: 10.1111/1744-9987.12058.
2
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.继发性甲状旁腺功能亢进:发病机制、疾病进展和治疗选择。
Clin J Am Soc Nephrol. 2011 Apr;6(4):913-21. doi: 10.2215/CJN.06040710. Epub 2011 Mar 31.
3
Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients.
慢性透析患者继发性甲状旁腺功能亢进管理的临床实践指南
Ther Apher Dial. 2008 Dec;12(6):514-25. doi: 10.1111/j.1744-9987.2008.00648.x.
4
Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease.慢性肾脏病黑人患者矿物质代谢紊乱的患病率及严重程度
Kidney Int. 2008 Apr;73(8):956-62. doi: 10.1038/ki.2008.4. Epub 2008 Feb 6.
5
Autosomal dominant polycystic kidney disease.常染色体显性多囊肾病
Lancet. 2007 Apr 14;369(9569):1287-1301. doi: 10.1016/S0140-6736(07)60601-1.
6
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.慢性肾脏病患者血清维生素D、甲状旁腺激素、钙和磷异常的患病率:评估早期肾脏疾病的研究结果
Kidney Int. 2007 Jan;71(1):31-8. doi: 10.1038/sj.ki.5002009. Epub 2006 Nov 8.
7
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.帕立骨化醇胶囊用于治疗3期和4期慢性肾脏病继发性甲状旁腺功能亢进。
Am J Kidney Dis. 2006 Feb;47(2):263-76. doi: 10.1053/j.ajkd.2005.10.007.
8
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.成纤维细胞生长因子-23可减轻慢性肾脏病患者的高磷血症,但会加重其骨化三醇缺乏。
J Am Soc Nephrol. 2005 Jul;16(7):2205-15. doi: 10.1681/ASN.2005010052. Epub 2005 May 25.
9
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.维持性血液透析中的矿物质代谢、死亡率和发病率
J Am Soc Nephrol. 2004 Aug;15(8):2208-18. doi: 10.1097/01.ASN.0000133041.27682.A2.
10
Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure.阿法骨化醇治疗18个月对轻至中度慢性肾衰竭患者骨骼的影响。
Nephrol Dial Transplant. 2004 Apr;19(4):870-6. doi: 10.1093/ndt/gfg595.